Literature DB >> 2013044

Pneumocystis carinii pneumonia associated with profound lymphopenia and abnormal T-lymphocyte subset ratios during treatment for early-stage breast carcinoma.

M W Brunvand1, C Collins, R B Livingston, G Raghu.   

Abstract

Two women with Stage II breast carcinoma treated with lumpectomy followed by breast irradiation and adjuvant chemotherapy developed Pneumocystis carinii pneumonia while receiving cytotoxic chemotherapy. Neither woman had evidence of immunosuppression before therapy. They both had profound lymphopenia, reversed CD4/CD8 ratios, and normal peripheral blood total leukocyte counts at the time of their infections. Both women were seronegative for human immunodeficiency virus type 1 and had no risk factors for such an infection. The patients' CD4 lymphocyte counts increased after chemotherapy for breast carcinoma was discontinued. Thus, it appears that the therapy they received may have caused severe T-lymphocyte mediated immunosuppression.

Entities:  

Mesh:

Year:  1991        PMID: 2013044     DOI: 10.1002/1097-0142(19910501)67:9<2407::aid-cncr2820670932>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Pneumocystis jiroveci Pneumonia in an Atypical Host.

Authors:  Raquel E Reinbolt; Shadia Alam; Rachel Layman; Charles Shapiro; Maryam Lustberg
Journal:  Clin Breast Cancer       Date:  2011-12-01       Impact factor: 3.225

2.  Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice.

Authors:  J B Roths; C L Sidman
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

3.  Absolute lymphocyte count as a predictor of Pneumocystis pneumonia in patients previously unknown to have HIV.

Authors:  Aghogho A Omene; Robert P Ferguson
Journal:  J Community Hosp Intern Med Perspect       Date:  2012-04-30

4.  A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.

Authors:  Lynn Symonds; Isaac Jenkins; Hannah M Linden; Brenda Kurland; Julie R Gralow; Vijayakrishna V K Gadi; Georgiana K Ellis; Qian Wu; Eve Rodler; Pavani Chalasani; Xiaoyu Chai; Jinny Riedel; Alison Stopeck; Ursa Brown-Glaberman; Jennifer M Specht
Journal:  Clin Breast Cancer       Date:  2021-05-24       Impact factor: 3.225

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.